List of Tables
    Table 1. Kidney Fibrosis Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Kidney Fibrosis Treatment Market Trends
    Table 3. Kidney Fibrosis Treatment Market Drivers
    Table 4. Kidney Fibrosis Treatment Market Challenges
    Table 5. Kidney Fibrosis Treatment Market Restraints
    Table 6. Global Kidney Fibrosis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Kidney Fibrosis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Kidney Fibrosis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Kidney Fibrosis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Kidney Fibrosis Treatment Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Kidney Fibrosis Treatment Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Kidney Fibrosis Treatment Revenue Share by Player, 2017-2022
    Table 13. Global Kidney Fibrosis Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Kidney Fibrosis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2021)
    Table 15. Top Players of Kidney Fibrosis Treatment in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Kidney Fibrosis Treatment Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Kidney Fibrosis Treatment Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Kidney Fibrosis Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Kidney Fibrosis Treatment Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Kidney Fibrosis Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Kidney Fibrosis Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Kidney Fibrosis Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Kidney Fibrosis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Kidney Fibrosis Treatment Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Kidney Fibrosis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Kidney Fibrosis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Kidney Fibrosis Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Merck and Co(US) Company Details
    Table 31. Merck and Co(US) Business Overview
    Table 32. Merck and Co(US) Kidney Fibrosis Treatment Product
    Table 33. Merck and Co(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 34. Merck and Co(US) Recent Development
    Table 35. Pfizer Inc(US) Company Details
    Table 36. Pfizer Inc(US) Business Overview
    Table 37. Pfizer Inc(US) Kidney Fibrosis Treatment Product
    Table 38. Pfizer Inc(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 39. Pfizer Inc(US) Recent Development
    Table 40. F. Hoffman-La Roche(Switzerland) Company Details
    Table 41. F. Hoffman-La Roche(Switzerland) Business Overview
    Table 42. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product
    Table 43. F. Hoffman-La Roche(Switzerland) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 44. F. Hoffman-La Roche(Switzerland) Recent Development
    Table 45. InterMune Inc(US) Company Details
    Table 46. InterMune Inc(US) Business Overview
    Table 47. InterMune Inc(US) Kidney Fibrosis Treatment Product
    Table 48. InterMune Inc(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 49. InterMune Inc(US) Recent Development
    Table 50. Galectin Therapeutics(US) Company Details
    Table 51. Galectin Therapeutics(US) Business Overview
    Table 52. Galectin Therapeutics(US) Kidney Fibrosis Treatment Product
    Table 53. Galectin Therapeutics(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 54. Galectin Therapeutics(US) Recent Development
    Table 55. La Jolla Pharmaceutical Company(US) Company Details
    Table 56. La Jolla Pharmaceutical Company(US) Business Overview
    Table 57. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product
    Table 58. La Jolla Pharmaceutical Company(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 59. La Jolla Pharmaceutical Company(US) Recent Development
    Table 60. ProMetic Life-Sciences Inc(Canada) Company Details
    Table 61. ProMetic Life-Sciences Inc(Canada) Business Overview
    Table 62. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product
    Table 63. ProMetic Life-Sciences Inc(Canada) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 64. ProMetic Life-Sciences Inc(Canada) Recent Development
    Table 65. BioLine Rx(Israel) Company Details
    Table 66. BioLine Rx(Israel) Business Overview
    Table 67. BioLine Rx(Israel) Kidney Fibrosis Treatment Product
    Table 68. BioLine Rx(Israel) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 69. BioLine Rx(Israel) Recent Development
    Table 70. Genzyme Corporation(US) Company Details
    Table 71. Genzyme Corporation(US) Business Overview
    Table 72. Genzyme Corporation(US) Kidney Fibrosis Treatment Product
    Table 73. Genzyme Corporation(US) Revenue in Kidney Fibrosis Treatment Business (2017-2022) & (US$ Million)
    Table 74. Genzyme Corporation(US) Recent Development
    Table 75. Research Programs/Design for This Report
    Table 76. Key Data Information from Secondary Sources
    Table 77. Key Data Information from Primary Sources
List of Figures
    Figure 1. Kidney Fibrosis Treatment Product Picture
    Figure 2. Global Kidney Fibrosis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Kidney Fibrosis Treatment Market Size 2017-2028 (US$ Million)
    Figure 4. United States Kidney Fibrosis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Kidney Fibrosis Treatment Market Size 2017-2028 (US$ Million)
    Figure 6. United States Kidney Fibrosis Treatment Market Share in Global 2017-2028
    Figure 7. Kidney Fibrosis Treatment Report Years Considered
    Figure 8. Product Picture of Angiotensin Converting Enzyme (ACE) Inhibitors
    Figure 9. Product Picture of Pirfenidone
    Figure 10. Product Picture of Renin Inhibitors
    Figure 11. Product Picture of Angiotensin II Receptor Blockers (ARBs)
    Figure 12. Product Picture of Vasopeptidase Inhibitors
    Figure 13. Global Kidney Fibrosis Treatment Market Share by Type in 2022 & 2028
    Figure 14. Global Kidney Fibrosis Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Kidney Fibrosis Treatment Market Share by Type (2017-2028)
    Figure 16. United States Kidney Fibrosis Treatment Market Share by Type in 2022 & 2028
    Figure 17. United States Kidney Fibrosis Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Kidney Fibrosis Treatment Market Share by Type (2017-2028)
    Figure 19. Product Picture of Chronic Kidney Diseases
    Figure 20. Product Picture of Kidney Cancer Treatment
    Figure 21. Product Picture of Others
    Figure 22. Global Kidney Fibrosis Treatment Market Share by Application in 2022 & 2028
    Figure 23. Global Kidney Fibrosis Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Kidney Fibrosis Treatment Market Share by Application (2017-2028)
    Figure 25. United States Kidney Fibrosis Treatment Market Share by Application in 2022 & 2028
    Figure 26. United States Kidney Fibrosis Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Kidney Fibrosis Treatment Market Share by Application (2017-2028)
    Figure 28. North America Kidney Fibrosis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Kidney Fibrosis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Kidney Fibrosis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Kidney Fibrosis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Kidney Fibrosis Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. UAE Kidney Fibrosis Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Merck and Co(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 57. Pfizer Inc(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 58. F. Hoffman-La Roche(Switzerland) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 59. InterMune Inc(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 60. Galectin Therapeutics(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 61. La Jolla Pharmaceutical Company(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 62. ProMetic Life-Sciences Inc(Canada) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 63. BioLine Rx(Israel) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 64. Genzyme Corporation(US) Revenue Growth Rate in Kidney Fibrosis Treatment Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed